Response Oncology Key Fundamental Indicators
Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Response Oncology, as well as the relationship between them.
Response Oncology's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Response Oncology's valuation are provided below:Response Oncology does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Response |
Search Suggestions
| RO | Roche Holding AG | CompanyDelisted |
| ROG | Rogers | Company |
| ROBAX | Robinson Tax Advantaged | Mutual Fund |
| ROE | Astoria Quality Kings | ETF |
| ROSE | Oasis Labs | Cryptocurrency |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Response Oncology has a Return On Equity of -7.2393. This is much lower than that of the Health Care Providers & Services sector and significantly lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Response Oncology Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Response Oncology's current stock value. Our valuation model uses many indicators to compare Response Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Response Oncology competition to find correlations between indicators driving Response Oncology's intrinsic value. More Info.Response Oncology is rated fourth in return on equity category among its peers. It is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Response Oncology's earnings, one of the primary drivers of an investment's value.Response Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Response Oncology's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Response Oncology could also be used in its relative valuation, which is a method of valuing Response Oncology by comparing valuation metrics of similar companies.Response Oncology is currently under evaluation in return on equity category among its peers.
Response Fundamentals
| Return On Equity | -7.24 | |||
| Return On Asset | -0.0153 | |||
| Profit Margin | (0.47) % | |||
| Operating Margin | (0.01) % | |||
| Current Valuation | 16.62 M | |||
| Shares Outstanding | 12.18 M | |||
| Revenue | 118.08 M | |||
| Gross Profit | 28.17 M | |||
| EBITDA | 1.32 M | |||
| Net Income | (51.39 M) | |||
| Cash And Equivalents | 9.01 M | |||
| Cash Per Share | 0.74 X | |||
| Total Debt | 26.45 M | |||
| Current Ratio | 13.35 X | |||
| Book Value Per Share | (1.54) X | |||
| Cash Flow From Operations | 9.1 M | |||
| Earnings Per Share | (4.16) X | |||
| Number Of Employees | 10 | |||
| Beta | -19.24 | |||
| Market Capitalization | 12 | |||
| Total Asset | 28.9 M | |||
| Retained Earnings | (120.16 M) | |||
| Working Capital | 34.72 M | |||
| Current Asset | 37.25 M | |||
| Current Liabilities | 2.54 M | |||
| Z Score | -0.15 | |||
| Net Asset | 28.9 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Response Stock
If you are still planning to invest in Response Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Response Oncology's history and understand the potential risks before investing.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |